Our Research Program

​Our clinical research program aims to understand the indications, treatment modalities, and mechanisms of psychedelic-assisted therapies for psychological and existential needs in patients with cancer. Read below our current areas of focus, which are grounded in our patient-centered approach. 

Indications

Existential distress ​& existential growth
​Opioid-refractory pain
Adjustment disorder
Depression

​         Modalities

​   Access
      Psilocybin, MDMA, and ketamine-assisted therapies
   Individual, group, dyadic approaches
    Music and psychedelics
    Spiritual care and psychedelics
Diversity, equity, and reciprocity
Clinician education & training
Implementation of PAT models into serious illness care

Ongoing Research Studies

  • Pilot study of Psilocybin-Assisted Therapy for demoralization in patients receiving Hospice care – PATH study (NCT04950608) 
  • Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients with Advanced Cancer- Cancer-related pain study
  • Opportunities and barriers for therapists of colors to engage in psychedelic research – Psychedelic Therapists Diversity study
  • MDMA-assisted Therapy for Adjustment Disorder (AD) in Dyads of Patients With Cancer and a Concerned Significant Other - MDMA dyad study collaboration with Sunstone Therapies (NCT05584826)​
  • Prevalence of demoralization, mood disorders and death anxiety and their association in an outpatient palliative care setting
To learn more, contact [email protected]